GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
136 articles on this topic
-
Semaglutide and Alcohol: What to Know
There is no listed direct interaction between semaglutide and alcohol, but the combination can make nausea, dehydration, low blood sugar, and pancreatitis risk more important.
-
What Happens When You Stop Taking Semaglutide
Appetite commonly returns as semaglutide clears, and some weight regain is likely. Trials show why stopping is better treated as a long-term care decision than as a test of willpower.
-
Does Tirzepatide Make You Tired? What Trials Say
Fatigue was reported by 5–7% of trial participants on tirzepatide against 3% on placebo. The more useful question is what is actually causing it.
-
Does Insurance Cover Tirzepatide? 2026 Guide
Insurance may cover Mounjaro for type 2 diabetes, while Zepbound coverage for obesity or sleep apnea depends on the plan. Compounded tirzepatide is generally self-pay.
-
How Long Does Tirzepatide Stay in Your System?
Tirzepatide usually takes about 25–30 days to fall to a small fraction of its starting level after the last dose. Its five-to-six-day half-life explains that estimate, but side effects and clinical effects do not end on one exact day.
-
Tirzepatide Diarrhea: How Long It Lasts
Diarrhea is common with tirzepatide, especially after treatment begins or the dose increases. It is usually temporary, but persistent symptoms can cause dehydration and deserve a clinician's attention.
-
Is Tirzepatide Safe? What the Evidence Shows
Safety is not a property of the molecule. It is the dose, the source of the vial, your own medical history, and whether a licensed clinician is accountable for the decision.
-
Oral Semaglutide: How the Semaglutide Pill Works
Estimated absolute bioavailability is about 0.4% to 1% for Rybelsus tablets and about 1% to 2% for Ozempic and Wegovy tablets; all three labels require fasting administration with up to 4 ounces of water and a 30-minute wait. Promise's compounded semaglutide formulation discussed here is an injectable solution.
-
Tirzepatide vs Retatrutide: How They Compare
Tirzepatide is a dual GIP/GLP-1 agonist with completed phase 3 trials and approved U.S. indications. Retatrutide is an investigational triple agonist that cannot be prescribed here yet — and that, not potency, is the difference that matters.
-
Is Semaglutide Safe? What the Evidence Shows
Semaglutide has years of trial data and a defined risk profile, but safe is not universal. Eligibility depends on personal history, other medicines, monitoring and exactly what product is dispensed.
-
Tirzepatide and Thyroid Cancer: What We Know
The boxed warning comes from thyroid C-cell tumors in rats, not proof of human cancer. Human studies conflict, so MTC and MEN 2 history remains the decisive screening issue.
-
Tirzepatide Weight Loss Results by Month
In SURMOUNT-1, average weight loss reached 15.0% to 20.9% at 72 weeks, depending on dose. The first month was only the initiation phase, and results varied widely.
-
Switching From Semaglutide to Tirzepatide
There is no validated milligram equivalence between the two molecules. Tirzepatide restarts at its own labeled starting dose no matter where the semaglutide dose ended, and a prescriber sets the timing.
-
Tirzepatide and Alcohol: The Risks That Matter
There is no alcohol contraindication in the labelling. The real issues are additive nausea, low blood sugar with certain diabetes medicines, a stomach that empties slowly, and pancreatitis risk arriving from two directions.
-
Tirzepatide for Sleep Apnea: What Was Approved
In December 2024 Zepbound became the first medicine approved in the United States for moderate-to-severe obstructive sleep apnea in adults with obesity. The trials behind it are specific, and so is what that approval does and does not cover.
-
Semaglutide Cost: Brand, Self-Pay and Compounded
Wegovy lists near $1,350 a month and Ozempic near $1,040, while the manufacturer's own self-pay channel charges $349 and eligible Medicare beneficiaries now pay a $50 copay. Same molecule, four very different bills.
-
Semaglutide for Type 2 Diabetes: What Trials Show
Brand semaglutide is approved for glycemic control in adults with type 2 diabetes, and the trial record now runs past blood sugar into heart and kidney outcomes. Compounded semaglutide is a different thing again — here is what separates them.
-
How to Inject Semaglutide Safely
Semaglutide goes into the fatty layer beneath the skin of the abdomen, front of the thigh, or back of the upper arm. The device and pharmacy label—not a generic online diagram—determine the exact technique and measured amount.
-
Is Tirzepatide a Peptide? A Clear Answer
Yes. Tirzepatide is a 39-amino-acid synthetic peptide, and it is also a dual GIP/GLP-1 receptor agonist. Those labels describe its structure and its action, respectively.
-
Tirzepatide Units to Mg: The Safe Conversion
Tirzepatide units to mg is not a fixed conversion. On a U-100 syringe, 20 units is 0.2 mL; the milligram amount depends on the vial concentration.
Page 6 of 7 · 136 articles